Description

RGDV is a platelet aggregation inhibitor. RGDV inhibits platelet-dependent thrombus formation. RGDV is used for tumor recognition via the targeting effect[1][2].—Cancer-programmed cell death–C17H31N7O7—-[1]Cadroy Y, et, al. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model. J Clin Invest. 1989 Sep;84(3):939-44.|[2]Wang F, et, al. Preparation and biological evaluation of tumor-specific Ara-C liposomal preparations containing RGDV motif. J Pharm Sci. 2012 Dec;101(12):4559-68.–93674-99-8–445.47—-O=C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(O)=O)=O)=O)[C@H](CCCNC(N)=N)N–Cancer–10 mM in DMSO–Others—-Others–Peptides